A colloidal suspension of hyaluronic acid and Sn-117m is used to treat joint inflammation. In one embodiment, Sn-117m is bonded to hyaluronic acid. Alternately, the Sn-117m can be dissolved in the hyaluronic acid colloidal suspension. This is injected into an inflamed joint, providing short-term and long-term relief.

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

A method for labeling exosomes with a radioactive substance using an amine group on surfaces of the exosomes includes providing a cell-derived exosome, treating a surface of the exosome with N-hydroxysuccinimide-azadibenzocyclooctyne (NHS-ADIBO), and mixing the treated exosome with N3-introduced chelator-radioactive substance to conduct a reaction between the chelator and an amine group present on the surface of the exosome, wherein the radioactive substance is introduced inside the exosome by the above reaction. The exosomes can be stably labeled at high labeling efficiency, and the exosomes can be favorably used as an agent for nuclear medicine imaging and therapeutic imaging for confirming the biological distribution of exosomes and whether the exosomes move to target organs and target diseases in animals including a human being.

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

A radioisotope elution system is provided that has a component in a cabinet with a door equipped with an authentication system to open. The system may also have a user interface equipped with an authentication system. The radioisotope elution system has a dose calibrator equipped with a lifting mechanism for lifting and/or lowering the vial to be tested in the dose calibrator. The lifting mechanism may be controlled for preventing the vial from being lifted during a quality control test on a sample of eluate in the vial. This feature prevents a user from tampering and/or interfering with the vial while a quality control testing is in progress. There also is provided a radioisotope elution system with a scanning system for entering information about the radioisotope generator and/or the patient in the system. Systems ensuring that the eluant reservoir contains a saline solution are proposed.

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

A method of preparing a radioactive yttrium salt particle suspension comprising multiple steps comprising: using a hydrothermal process wherein a solution of soluble yttrium salt, from the group of yttrium chloride, yttrium nitrate, yttrium sulfate, and yttrium bromide is combined with a solution of sodium phosphate having a stoichiometric excess of phosphate and a preferred pH when combined.

A radioactive thermogel suspension, including a thermogel and a plurality of insoluble radioactive isotope phosphate particles, such as yttrium phosphate, suspended in the thermogel. The thermogel is PLGA-g-PEG. The thermogel contains less than 65 ppm stannous octanoate. The plurality of radioactive yttrium phosphate particles are between 0.03 m and 10 m in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 3 mg/ml to 100 mg/ml.

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.